Kim Blickenstaff

SenoRx, Inc. develops and manufactures invasive devices for the diagnosis and treatment of breast cancer. The company was founded in 1998 and is headquartered in Tempe, AZ.

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

MediSpectra, Inc. develops and manufactures medical devices. The firm develops proprietary optical detection technology for enhanced accuracy and real time results in the detection of cancer & other human tissue abnormalities. Its technology is based on multimodal optical interrogation of tissues with light. The company was founded in 1995 and is headquartered in Lexington, MA.

GeneOhm Sciences, Inc. develops molecular diagnostic products. It offers methicillin-resistant staphylococcus aureus (MRSA) Assay an in vitro diagnostic test for the direct detection of MRSA from a nasal specimen. The company was founded on 2001 and is headquartered in Franklin Lakes, NJ.

Micro Therapeutics, Inc. develops, manufactures and markets invasive medical devices for the diagnosis and treatment of vascular diseases. Its products include infusion catheters, ballon catheters, delivery catheters, guide wires, infusion wires, and thrombolytic brushes. The company was founded in 1993 and is headquartered in Irvine, CA

Founded in 1996, Amira Medical develops and markets glucose monitoring products. In particular, it has pioneered proprietary technology to enable users to draw a small blood sample from areas of the body other than the fingertips